GSA Capital Partners LLP Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

GSA Capital Partners LLP purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,642 shares of the company’s stock, valued at approximately $377,000.

A number of other hedge funds have also modified their holdings of MRNA. Commerzbank Aktiengesellschaft FI grew its holdings in Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the last quarter. CVA Family Office LLC raised its holdings in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC lifted its position in Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after acquiring an additional 108 shares during the last quarter. McAdam LLC boosted its holdings in Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after acquiring an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC grew its position in shares of Moderna by 1.1% in the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock valued at $1,826,000 after purchasing an additional 160 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 4.0 %

Shares of NASDAQ MRNA opened at $38.40 on Friday. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The business has a fifty day moving average of $56.13 and a two-hundred day moving average of $95.05. The stock has a market cap of $14.78 billion, a PE ratio of -6.60 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.39) earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and cut their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Berenberg Bank began coverage on Moderna in a research report on Tuesday. They issued a “hold” rating and a $42.00 price objective for the company. TD Cowen dropped their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a report on Monday. Finally, UBS Group dropped their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $84.00.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 2,930 shares of company stock valued at $217,170 in the last three months. 15.70% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.